에이비온

203400KOSDAQ

59.0 / 100

Reference Date: 2026-09-08

Financial Score20.0 / 40

News Sentiment18.0 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 4.5% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

ABION is a KOSDAQ-listed biopharmaceutical company specializing in the development of anti-cancer drugs and candidates based on companion diagnostics. Key pipelines include Vabametkib for non-small cell lung cancer, ABN101 (an interferon-beta-based antiviral), and ABN501 targeting Claudin3 protein in various cancers. Approximately 95.3% of its revenue comes from government research contracts.

Number of Employees

34people

Average Salary

72.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.89Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

-60.24Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

7.16Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼12.3% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲17.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -173.6% (improving, 3yr)

Detailed News Sentiment

16 totalPositive 4Neutral 1Negative 11Average Sentiment Score 71.9

Negative
주가 부진에 CB '부메랑' 맞은 바이오 기업들
바이오 기업들의 주가 하락으로 인해 전환사채의 가치가 하락하여 자금 조달에 어려움이 증가하고 있다.
Negative
동전주 퇴출에 약가 인하까지…벼랑 끝 몰린 중소 제약바이오
중소 제약바이오 기업들의 자금 조달 어려움과 약가 인하로 인해 위기 상황이 심화되고 있다.
Negative
"상폐 피하려 1000원 턱걸이"…당국, 동전株 점검
금융당국의 집중 모니터링과 유망 기업의 상장폐지 위기 언급으로 에이비온의 주가에 부정적 영향 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 676Won52-week high 4,10052-week low 616

1-month return4.0Point

1m +4.48% (slight rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0

Neutral기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)2026-09-07
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-18
Neutral주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))2026-08-14
Neutral임시주주총회결과2026-08-14
Neutral반기또는분기매출액미달사실발생2026-08-14